An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Food Allergy in Children and Young People: Diagnosis and Assessment of Food Allergy in Children and Young People in Primary Care and Community Settings.
London: National Institute for Health and Clinical Excellence (NICE); 2011 Feb. (NICE Clinical Guidelines, No. 116.)
Top results in this bookTable of Contents
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Upadacitinib can be used with or without topical corticosteroids [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.
Abrocitinib (Cibinqo): CADTH Reimbursement Recommendation: Indication: For the treatment of patients aged 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs (e.g., steroid or biologic), or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Atopic eczema in under 12s: diagnosis and management.
London: National Institute for Health and Care Excellence (NICE); 2023 Jun 7. (NICE Clinical Guidelines, No. 57.)
Dupilumab (Dupixent): CADTH Reimbursement Recommendation: Indication: For the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.
National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma.
Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2007 Aug.
Baby-Friendly Hospital Initiative: Revised, Updated and Expanded for Integrated Care.
Geneva: World Health Organization; 2009.
Tralokinumab (Adtralza): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Tralokinumab can be used with or without topical corticosteroids [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
CADTH Canadian Drug Expert Committee Recommendation: Dupilumab (Dupixent — Sanofi-Aventis Canada Inc.): Indication: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul.
Lebrikizumab (Ebglyss): Indication: For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov.
CADTH Canadian Drug Expert Committee Recommendation: Crisaborole (Eucrisa — Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.
WHO guideline on the prevention and diagnosis of rheumatic fever and rheumatic heart disease [Internet].
Geneva: World Health Organization; 2024.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
WHO recommendations on maternal and newborn care for a positive postnatal experience [Internet].
Geneva: World Health Organization; 2022.
Dupilumab (Dupixent): CADTH Reimbursement Recommendation: Indication: For the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.
Asthma [Internet].
Smith JD, Arteta M, Baptist AP, et al.
Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Jul.
Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes.
NICE Medicines and Prescribing Centre (UK).
Manchester: National Institute for Health and Care Excellence (NICE); 2015 Mar. (NICE Guideline, No. 5.)
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Upadacitinib may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Feeding Infants and Children from Birth to 24 Months: Summarizing Existing Guidance.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee on Scoping Existing Guidelines for Feeding Recommendations for Infants and Young Children Under Age 2; Harrison M, Dewey K, editors.
Washington (DC): National Academies Press (US); 2020 Jul 8.
Baricitinib (Olumiant): Indication: For the treatment of adult patients with severe alopecia areata: CADTH Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on